1. LILRB2 promotes immune escape in breast cancer cells via enhanced HLA-A degradation.
- Author
-
Jiang, Zhiyuan, Huang, Qianru, Chang, Yujie, Qiu, Yiran, Cheng, Hao, Yang, Mengdi, Ruan, Shunyi, Ji, Suyuan, Sun, Jing, Wang, Zhiyu, Xu, Shengyuan, Liang, Rui, Dai, Xueyu, Wu, Kejin, Li, Bin, Li, Dan, and Zhao, Hui
- Subjects
HLA histocompatibility antigens ,IMMUNOSTAINING ,T cells ,BREAST cancer ,CANCER cells - Abstract
Purpose: Increased expression of leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is associated with immune evasion in breast cancer (BC). The aim of this study to elucidate the role of LILRB2 in BC progression. Methods: LILRB2 expression in tumor tissues was detected by immunohistochemical staining. Human leukocyte antigen A (HLA-A) expression in BC cells was detected by Western blotting, and HLA-A ubiquitination was detected by immunoprecipitation and histidine pulldown assay. An in-situ tumor model was established in nude BALB/c mice to verify the role of LILRB2 in immune escape. Finally, the functions and potential mechanisms of LILRB2 in BC progression were explored using in silico data. Results: LILRB2 was upregulated in BC tissues and cells, and correlated positively with poor prognosis. LILRB2 promoted BC progression by downregulating HLA-A expression. Mechanistically, LILRB2 facilitates the ubiquitination and subsequent degradation of HLA-A by promoting the interaction between the ubiquitin ligase membrane-associated ring finger protein 9 (MARCH9) and HLA-A. In syngeneic graft mouse models, LILRB2-expressing BC cells evaded CD8 + T cells and inhibited the secretion of cytokines by the cytotoxic CD8 + T cells. Conclusion: LILRB2 downregulates HLA-A to promote immune evasion in BC cells and is a promising new target for BC treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF